NetworkNewsBreaks – PreveCeutical Medical Inc. (
Post# of 77
(Total Views: 203)
Posted On: 07/24/2018 6:19:24 PM
NetworkNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Launches Medicinal Cannabis Division
PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced the launch of a medicinal cannabis division, advancing PreveCeutical’s vision of becoming a global preventive healthcare company. The cannabis division’s responsibilities include bringing various high-quality, medicinal cannabis-based products to market and managing the company’s nasal delivery Sol-gel research program as well as any resulting formulations. The cannabis division’s products will include transdermal patches, topical creams, capsules and other methods of administering medicinal cannabis. “The opening of the cannabis division at this crucial moment is very exciting and continues to move the company in an important direction. With Canada’s upcoming legalization of recreational cannabis on October 17, 2018, and the reduction of stigma surrounding cannabis products, PreveCeutical sees a potential void in the medicinal cannabis sector as many companies begin to move to recreational market to accommodate demand. This market shift will provide PreveCeutical with the opportunity to focus on the healthcare sector and supply the increasing demand for effective and tailored cannabis-based therapies,” PreveCeutical Medical chairman, president and CEO Stephen Van Deventer stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced the launch of a medicinal cannabis division, advancing PreveCeutical’s vision of becoming a global preventive healthcare company. The cannabis division’s responsibilities include bringing various high-quality, medicinal cannabis-based products to market and managing the company’s nasal delivery Sol-gel research program as well as any resulting formulations. The cannabis division’s products will include transdermal patches, topical creams, capsules and other methods of administering medicinal cannabis. “The opening of the cannabis division at this crucial moment is very exciting and continues to move the company in an important direction. With Canada’s upcoming legalization of recreational cannabis on October 17, 2018, and the reduction of stigma surrounding cannabis products, PreveCeutical sees a potential void in the medicinal cannabis sector as many companies begin to move to recreational market to accommodate demand. This market shift will provide PreveCeutical with the opportunity to focus on the healthcare sector and supply the increasing demand for effective and tailored cannabis-based therapies,” PreveCeutical Medical chairman, president and CEO Stephen Van Deventer stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)